Upcoming Meetings in the Series:
4th ADC Target Selection Summit |
15th World ADC London
|
Novel Conjugates Summit
|
Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com
Leveraging Pharmacometric Insights to Identify an Optimal Dose for ADCs that Navigates Regulatory Expectations, Threads the Needle Between Safety & Efficacy & Drives Forward BLA Approval
Welcome to the ADC Pharmacokinetics & Clinical Pharmacology Summit
Finding the Optimal ADC Dosage the First Time
As the Antibody‐drug conjugates (ADCs) space continued to thrive in 2024, with 12 approvals and a growing number of diverse candidates being developed, getting the dosing spot on is pivotal for success in bringing safe and efficacious ADCs to patients, quicker.
In the face of evolving regulatory guidance and more complex ADCs entering development, the inaugural ADC Pharmacokinetics & Clinical Pharmacology Summit came to life in October 2024 to provide in-depth pharmacokinetic and clinical pharmacology insights to help ADC developers select a clinical dose that maximizes efficacy whilst limiting toxicities and drive more ADCs to BLA approval quicker.
As the next generation of ADCs becomes even more complex, this further emphasizes the need to integrate insights within PK/PD, bioanalysis, pharmacometrics and clinical pharmacology to support the tricky translation from non-clinical studies into clinical trials.
Attendees heard first-hand insights on establishing a clear mechanistic link between ADC design and PK profile, utilizing pharmacometrics and PK/PD data to inform dose optimization for FIH, later phase dosage and ADC combination therapies, taking practical insights back to your own department to curate a clear strategy for striking clinical success with your next ADC candidate.
Find Out More
The 2024 World-Class Speaker Faculty Included:
Lan Li
Senior Director - Clinical Science, Development, Oncology, Research & Development
Daiichi Sankyo, Inc.
Previously Attending Companies:
"For me, attending this meeting holds significant value. It provides an opportunity to learn from the best in the ADC field and gain knowledge that I can bring back to my team. The chance to discuss our work with others, receive feedback, and see how others approach similar problems is incredibly valuable this conference provided an excellent overview.”
Venkatesh Reddy,
Global PKPD and Pharmacometrics, Eli Lilly